New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
08:56 EDTACRXAcelRx price target lowered to $12 from $14 at JMP Securities
JMP Securities cut its price target on AcelRx after the company received a Complete Response Letter from the FDA. The firm thinks the requests in the letter were minor, and the firm now assumes that the launch of the drug will be delayed a year until early 2016. However, it sees a 90% chance of the drug being approved and keeps an Outperform rating.
News For ACRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ACRX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use